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Introduction: Dengue is vector-borne viral infection that endangers an estimated 2.5 
billion people. Disease caused by dengue ranges from a relatively minor febrile illness 
to  a life-threatening condition  characterised by  extensive capillary leak. A greater 
understanding of dengue has the potential to improve both the clinical management of 
individual cases and the control of the disease. 
 
Sources of data: We searched the available literature suing PubMed, Embase and 
Web of Science for relevant articles and abstracts. 
 
Areas  of  agreement:  Addressing  our  gaps  in  the  understanding  of  disease 
pathogenesis and improving our knowledge of dengue virus biology are necessary in 
order to develop tools to effectively control, diagnose and treat the disease. 
 
Areas of controversy: The pathogenesis of dengue is multifactorial and depends on 
both host and virus factors. A more integrated understanding of disease pathogenesis 
is necessary. 
 
Areas timely for developing research: There are many questions related to disease 
pathogenesis,  development  of  diagnostics,  drug  and  vaccine  development  and 
individual case management that need addressing if the disease is to be successfully 
tackled. 
 
Keywords:  Dengue  /  Dengue  Haemorrhagic  Fever  /  Dengue  Shock  Syndrome  / 
pathogenesis / vaccine / drug development  Introduction 
 
Dengue is a viral infection transmitted by Aedes mosquitoes.1 Dengue is a Flavivirus 
with  four  different  antigenically  distinct  serotypes  (DENV1-4).2,  3  It  is  a  rapidly 
growing  health  problem  with  an  estimated  2.5  billion  people  at  risk,  mainly  in 
countries of south and south-east Asia, the Caribbean, Central and South America, 
and  more  recently  in  Africa.4,  5  The  spread  of  dengue  is  thought  to  be  due  to 
combination  of  factors:  increased  urbanisation,  population  growth,  migration  and 
international travel and the difficulties of effective vector control.6 Climate change 
may be a contributing factor in the global spread of dengue.7 It is estimated that there 
are between 50 and 100 million cases of dengue each year, of which approximately 
500,000  are  severe  life-threatening  infections.8  There  have  been  numerous  urban 
outbreaks  of  dengue  with  significant  health  and  economic  impacts.9-11  Studies  in 
Thailand and Brazil have shown that the social and economic impact is equivalent to 
that of malaria in these countries.12,  13 However globally dengue research has not 
received the same level of funding as other tropical infectious diseases.8 There are 
currently no available drugs, no licensed vaccine and diagnosis in endemic areas is 
largely clinical.14 Dengue also poses a risk to those who travel to endemic areas and is 
increasingly being reported in travellers returning from trips to endemic countries.15 
 
Dengue viruses  cause a variety of clinical  syndromes  ranging from  asymptomatic 
infection to a self-limiting febrile illness to severe dengue, a life-threatening condition 
characterised by increased capillary permeability and shock.16-18 There are concerns 
that the old WHO definitions of dengue that are still in widespread use may lead to 
under-diagnosis of severe dengue.19 In clinically apparent dengue infection symptoms 
develop after an incubation period of 4 to 7 days with an abrupt onset of fevers often 
accompanied by headache with severe retro-orbital pain.20, 21 Some patients develop 
severe arthralgia, explaining the historical name of break-bone fever.22 Early in the 
illness  the  skin  may  appear  flushed,  with  petechiae  appearing  during  the  ‘critical 
phase’  and  a  macular  rash  appearing  in  early  convalescence.  Even  after 
uncomplicated  dengue  recovery  may  be  complicated  by  fatigue  and  depression. 
Thrombocytopenia is almost universal in dengue infection and minor bleeding from 
skin and mucosal surfaces may be seen in uncomplicated infections  - this can be 
severe in patients with peptic ulcer disease.23 Biochemical hepatitis is frequently seen in dengue infection but severe liver pathology, encephalitis and renal dysfunction are 
relatively  rare.21,  24  Data  from  Taiwan  show  differences  in  disease  manifestations 
between  adults  and  children  observed  during  an  outbreak  in  2002.25  Arthralgia, 
headache,  gastrointestinal  bleeding  and  significantly  severe  dengue  were  more 
common in adult patients. The reasons for these differences are not clear but could 
reflect differences in the host response to infection. Significant and disabling fatigue 
has been described after recovery from dengue.26 It is thought that host factors may 
contribute to the development of this condition. Vertical transmission of dengue can 
occur if infection of the mother occurs within 8 days of delivery.27 The WHO have 
recently  published  new  guidelines  on  dengue  management.28  The  new  guidelines 
indicate that disease caused by dengue encompasses a wide clinical spectrum and that 
the previously used classifications for severe dengue were not always helpful. Dengue 
is classified in the new system as either uncomplicated or severe.28  Severe disease is 
characterised  by  plasma  leak,  haemorrhage  and  organ  impairment.  Recognising 
warning signs  for severe disease is  important  for successful clinical  management. 
Warning  signs  include  abdominal  pain,  evidence  of  fluid  accumulation, 
hepatomegaly, and increases in haematocrit accompanied by fall in platelet count.28 
The mechanisms that lead to severe dengue are not completely understood although 
various hypotheses exist. Perhaps the most widely accepted hypothesis explaining the 
development  of severe  dengue is  that  of antibody-mediated immune enhancement 
where antibodies developed to a previous infection lead to enhanced viral uptake with 
a  new  infection  of  a  different  serotype.29,  30  This  and  other  hypotheses  will  be 
discussed in a later section of this review. 
 
Sources of data 
We searched the available literature up to April 2010 using PubMed, Web of Science 
and Embase using the terms: "dengue"; "dengue fever"; "dengue haemorrhagic fever"; 
and "dengue viruses". 
 
Areas of agreement 
As dengue has emerged as a global health threat it has received increased attention 
from the international public health community.14 Essentially areas of agreement are 
based  around  addressing  the  lack  of  effective  diagnostic  and  therapeutic  options, improving clinical care of affected patients, and developing tools to prevent dengue 
infection. 
 
 
Areas of controversy 
Is the virus itself or the host response to infection the main cause of severe disease? 
The 4 serotypes of dengue can be further classified into different genotypes based on 
nucleotide variation.31 Different genotypes have been associated with different levels 
of virulence.32, 33 It appears that the virus may evolve during epidemics to cause more 
severe disease as seen in disease outbreaks in Cuba and Australia.34,  35 It has been 
suggested that structural differences in strains of the virus lead to differing abilities to 
infect different cell types or cause severe disease.36,  37 However given that only a 
small percentage of patients infected with dengue develop severe disease it is clear 
that host factors have a major role to play in dengue pathogenesis.31 
 
Many of the clinical features of dengue infection may be due to the patients' immune 
response.  The increased vascular permeability seen in dengue is associated with high 
levels  of  cytokines  including  tumour  necrosis  factor  alpha  (TNF-),  interferon 
gamma (IFN-), interleukin six (IL-6) and interleukin two (IL-2).38, 39 However, it is 
important to note that these cytokines are elevated in many diseases yet dengue is a 
very specific clinical entity. Therefore the clinical features of dengue could be due to 
a specific constellation of these cytokines or a more complex interaction between host 
and virus that is yet to be characterised. Polymorphisms in TNF- are associated with 
more severe disease.40 Various other genetic factors have been associated with more 
severe  disease:  for  example  polymorphisms  in  the  vitamin  D  receptor  gene,  the 
mannose-binding lectin gene, and various HLA class I and II alleles.41-44 However, 
none of these studies have been large enough to indicate a clear association and the 
question  of  host  susceptibility  remains  unanswered.  Cytokine  dysregulation  and 
endothelial injury contribute to the pathogenesis of yellow fever, another flavivirus.45 
The  pathophysiology  of  severe  yellow  fever  infection  remain  unclear,  but  given 
similarities  with  severe  dengue  there  may  be  overlap  in  the  host  and  virus 
determinants of susceptibility. 
  
 
Is  the  hypothesis  of  antibody-mediated  enhancement  sufficient  to  explain  the 
development of severe disease? 
Epidemiological studies have shown that severe disease is more commonly seen after 
secondary  infections.46  Infection  with  one  serotype  is  thought  to  result  in  brief 
protection against all serotypes. As the levels of neutralising antibodies fall over time 
the  non-neutralising  or  sub-neutralising  antibodies  form  complexes  with  the  new 
infecting virus and these complexes are taken up by Fc-receptor bearing cells. This 
results in increased uptake of virus, increased replication and viral load and hence a 
postulated  increased  likelihood  of  complications.30  This  phenomenon  explains  the 
severe disease observed in infants aged between 6 and 9 months where the low non-
neutralising levels of maternally derived antibodies are thought to play a crucial role 
in the development of severe disease.47, 48 These observations have led to concerns 
that a vaccine may potentially result in more severe disease by priming the immune 
system and putting individuals at risk when they are subsequently infected.  These 
fears are ungrounded if such a vaccine produces long term neutralising protection to 
all 4 serotypes and those serotypes do not change over time.3 However, severe disease 
can occur in primary infections and most secondary infections do not result in severe 
disease indicating that other factors contribute.49,50,51 Direct evidence for antibody-
dependent enhancement (ADE) contributing to the development of severe disease in 
humans has been difficult to demonstrate although recent work in infants and from 
elegant in vitro and clinical studies is starting to yield crucial insights into how ADE 
may contribute to pathogenesis.51, 52 
 
The pathogenesis of dengue is complex and multifactorial. No hypothesis in isolation 
is sufficient to explain the development of severe disease. It is the interplay between 
virus  factors  and  genetically  determined  host  factors  that  determine  the  disease 
outcome in the individual patient.  
 
Growing points - areas timely for developing research 
Increased understanding of dengue pathogenesis 
As  discussed  above  the  mechanisms  that  lead  to  severe  dengue  are  incompletely 
understood. A greater and clearer understanding of disease pathogenesis including host genetics, virus biology and immunopathology, would help the development of 
targeted  clinical  interventions.14  Clarifying  how  dengue  virus  virulence  varies 
between  serotypes  and  evolves  within  epidemics  would  be  helpful.  Do  different 
serotypes vary in their tissue tropism thus explaining differences in disease severity? 
Elucidating  how  the  different  factors  within  the  immune  system  interact  and 
contribute to disease development is essential. Too often research focuses on a single 
aspect of the immune response, be it antibody-mediated enhancement, T and B cell 
responses  or  the  role  of  complement  when  a  more  integrated  view,  including 
consideration of the virus, is required.31  
 
NSI is a glycoprotein secreted by dengue-infected cells. Early detection of NSI has 
demonstrated efficacy as a diagnostic tool.54 Its role in dengue pathogenesis is unclear 
– defining this role may lend weight to its use in diagnostics. It is possible that it 
activates complement at endothelial surfaces thus contributing to the vascular leak 
that occurs in  severe disease.55 Clarifying the events  that occur at  the endothelial 
surface in dengue infection would be a major advance - the development of a suitable 
animal model of dengue infection would aid this progress.56 
 
An increased understanding of genetic factors that contribute to disease development 
would help define more clearly populations at risk. Within populations an increased 
understanding of differing susceptibilities to disease development is necessary.31 
 
Optimisation of clinical management 
The commonly used WHO guidelines for the management of dengue were developed 
after observations in children hospitalised in Bangkok in the 1960s with dengue.19 
These guidelines have evolved over the years and have been adopted into clinical 
practice in endemic areas. An attempt to validate the WHO classifications for severe 
disease  has  been  recently  published.57  This  study  showed  that  while  the  WHO 
classifications had good specificity for severe disease the sensitivity was lower. There 
is no doubt that the use of the guidelines have led to substantial mortality reductions, 
yet  are  guidelines  originally  developed  for  Thai  children  forty  years  ago  still 
applicable  today  or  for  example  in  the  increasing  number  of  adult  patients  seen 
globally?19, 58 
 One of the difficulties diagnosing dengue haemorrhagic fever (DHF) using the old 
WHO definitions was that the criteria were too rigid.16 Studies have shown that many 
cases  of  dengue  that  resulted  in  shock  or  death  did  not  meet  the  WHO  case 
definitions.59,  60  These  problems  have  led  to  the  development  of  the  new  WHO 
guidelines  that  categorise  dengue  cases  into  uncomplicated  or  severe.28  These 
guidelines  emphasise  the  importance  of  recognising  the  warning  signs  of  severe 
dengue - abdominal pain, vomiting, fluid accumulation, mucosal bleeding, lethargy or 
restlessness, hepatomegaly, rising haematocrit in conjunction with falling platelets.28 
These  2009  WHO  guidelines  include  a  detailed  description  of  the  clinical 
management  of  dengue  including  an  algorithm  for  the  management 
(http://whqlibdoc.who.int/publications/2009/9789241547871_eng.pdf).    A  challenge 
is educating healthcare workers about the new guidelines and ensuring that they result 
in better clinical care. 
  
The  mortality  in  severe  dengue  remains  significant  particularly  in  infants.50,  61  In 
addition higher mortality rates are seen when dengue newly emerges in regions where 
there is less experience in clinical management of cases, for example as seen in the 
epidemics in  India and  Brazil.10,  62 Fluid management in  dengue is  difficult  - the 
balance between too much and too little is critical and getting it wrong can be life-
threatening.63 Fluid resuscitation is not without risk and fluid overload in the recovery 
phase can cause acute respiratory distress syndrome (ARDS).28   Fluid management in 
patients with co-morbidities or pregnancy is difficult and would benefit from further 
research. 
 
It is likely that there is a significant unreported burden of mortality in remote health 
facilities where clinical management maybe poor. Early and careful administration of 
parenteral fluids is life saving in severe dengue. Ringer's lactate has demonstrated 
efficacy for use in  dengue shock syndrome and dextran or starch have also  been 
suggested  for  severe  disease.64  Successful  management  of  severe  dengue  requires 
favourable  staff  to  patient  ratios  and  the  ability  to  closely  monitor  patients.28 
Unfortunately the use of parenteral fluids and the intense monitoring that is required 
may  not  always  be  available  and  there  is  a  need  for  research  on  the  use  of  oral 
rehydration therapy aimed at preventing the development of shock in severe dengue.14  
 The endothelial leak seen in severe dengue is transient and if appropriate supportive 
therapy is given during this period mortality rates are low.16 However in the early 
stages of disease clinical features are non-specific and are shared with other infectious 
aetiologies.61 Making a diagnosis early in the disease would significantly aid clinical 
management.  Additionally  predicting  which  patients  are  at  risk  of  severe  disease 
would be a major advance. Traditionally diagnosis has relied on serology, which can 
take time to give useful results meaning diagnosis is often retrospective.1 IgM against 
dengue can be detected after 5 days of fever - commercially available diagnostic kits 
based on ELISA have been assessed.65 These have potential but have limitations, for 
example the persistence of IgM in some patients in endemic areas making it difficult 
to  diagnose  an acute infection. The detection of the dengue protein  NSI also  has 
proven use in diagnosis.54 Quantifying the titre of NSI early in clinical illness may 
allow one to predict those at risk of developing severe disease.66 Real-time PCR is 
another potential, highly sensitive diagnostic tool in dengue diagnosis.67 However the 
cost of molecular tests  such as PCR make it an impractical tool for use in many 
settings where dengue is prevalent.  A rapid sensitive test that combines detection of 
NS1,  IgG  and  IgM  allowing  diagnosis  of  infection  throughout  the  illness  course 
would be a major advance in dengue diagnostics. The development of appropriate 
clinical algorithms for use in resource-limited settings in parallel to the development 
of molecular diagnostic tools is necessary if the burden of dengue is to be adequately 
dealt with. A study has demonstrated the potential use of a decision tree algorithm 
using simple clinical and haematological parameters.68 Testing the validity of such an 
algorithm in primary care settings have the potential to improve the triage and initial 
clinical management of patients with dengue. Detection of plasma leakage through 
serial ultrasound is a useful adjunctive tool in dengue diagnosis and management yet 
it is unlikely to be of benefit in many areas due to lack of availability.69 Identifying 
additional  predictors  of  dengue  would  be  useful  -  making  these  into  diagnostic 
techniques that are practical in resource-limited settings is the challenge.70  
 
Vaccine development 
A vaccine against dengue would be a major advance in the control of the disease. In 
view of the potential risks of antibody-mediated enhancement seen with heterotypic 
infections a successful vaccine would have to offer lasting protection against all 4 
serotypes.2 Based on the success of vaccination against other flaviviruses, for example Japanese encephalitis and yellow fever, the development of a live attenuated vaccine 
had  previously  been  the  most  promising  prospect  for  vaccinologists.71  However 
despite  encouraging  results  with  monovalent  vaccines  in  clinical  trials  the 
development of a tetravalent formulation has proved problematic and development 
has been suspended.3,  72-75  The leading vaccine candidate at present is a chimeric 
vaccine - a recombinant clone based on yellow fever vaccine strain with dengue virus 
membrane  and  envelope  protein  genes  substituted  into  the  construct.76,  77  This 
chimeric vaccine has shown promise in Phase II clinical trials and appears safe and 
immunogenic.  It is anticipated that Phase III trials will start in the near future.   
 
Despite  promising  progress  there  remain  unanswered  questions  that  need  to  be 
addressed and are potential areas for research. The lack of a suitable animal model of 
dengue infection hinders the transfer of laboratory findings into clinical practice.31 
How do we quantify immune protection? Do tetravalent vaccine constructs hinder the 
development of immunity to individual serotypes? Could a dengue vaccine render 
populations  more vulnerable to  severe infection, either through antibody-mediated 
enhancement or via a mechanism similar to that seen with vaccines against respiratory 
syncytial  virus?78  How  safe  are  dengue  vaccines  in  different  subsets  of  the 
population?3  
 
In addition to the science of vaccine development and questions regarding the safety 
and  efficacy  of  individual  vaccine  candidates  there  needs  to  be  sustained  co-
ordination between different countries and vaccine developers if a vaccine is to be 
successfully developed.79  
 
Anti-dengue drugs 
A greater understanding of dengue virus biology has meant that targets within the 
lifecycle  have  been  identified  that  could  potentially  be  the  site  of  a  therapeutic 
agent.80 The staggering success in developing drugs against HIV is an example of 
how efficiently effective antivirals can be developed given appropriate funding.   
 
One potential mechanism of action of an anti-dengue drug is through inhibition of 
viral entry. The fusion of the viral membrane with the host membrane is mediated by 
dengue  virus  E  protein.81  Research  has  shown  some  promising  initial  results  in laboratory studies with an experimental entry inhibitor - these findings could pave the 
way to  the development of successful  therapeutic agents.82 Other potential targets 
receiving  research  attention  are  the  viral  proteins  NS3  and  NS5,  which  play  an 
integral  role  in  genome  replication  -  their  protease  domains  could  be  target  for 
protease inhibitors.83,  84 A computer programme has been used to identify suitable 
molecules that can "dock" into the NS3 protease domain.85 The challenge is to bridge 
the  gap  between  findings  in  the  laboratory  and  the  bedside  however  given  the 
progress in our understanding of dengue virus biology the future of drug development 
is encouraging.  There are potential therapeutic developments for the treatment of 
other  flaviviruses  such  as  hepatitis  C.86  In  view  of  structural  similarities  between 
different  flaviviruses  these  developments  could  be  used  in  the  field  of  dengue 
treatment. The complications of dengue occur as the virus is cleared from the blood so 
it is possible that an anti-dengue drug will have no beneficial role. As the severe 
manifestations  of  disease  are  in  part  due  to  the  immune  response  perhaps  the 
development of an immunomodulatory agent would be the best therapeutic strategy? 
Animal studies have shown the protective effect of monoclonal antibodies against the 
NS1  protein  of  West  Nile  virus,  and  more  recent  work  in  mice  has  shown  the 
therapeutic potential of a monoclonal antibody directed against a structural epitope in 
an experimental DENV-1 infection.87, 88 
 
Vector control 
In  addition  to  vaccination  successful  vector  control  would  be  a  useful  adjunct  to 
controlling  dengue.  Dengue  is  closely  associated  with  Aedes  aegypti  -  the  global 
spread  of  dengue  is  related  to  changes  in  human  behaviour,  in  particular  the 
expansion of large urban centres,  that support the breeding of  A. aegypti.6 While 
vector control has previously had success the persistence of pockets of mosquitoes 
resulted  in  disease  re-emergence.89  Studies  have  shown  different  efficiencies  of 
dengue transmission between different  mosquito strains  and different  serotypes  of 
dengue.90, 91 A greater understanding of the interactions between mosquitoes and the 
different serotypes of dengue would give us a greater understanding of transmission 
dynamics and would potentially lead to better prediction of epidemics and thus better 
control of the disease. The development of genetically modified mosquitoes that are 
less  able  to  transmit  dengue  is  a  potential  option  for  disease  control.  However 
mathematical models have indicated that this strategy may select for greater disease virulence suggesting that  measures  that increase mosquito mortality may  be more 
effective.92 Transgenic mosquitoes are likely to be less reproductively fit - infection of 
transgenic  mosquitoes  with  the  symbiont  Wolbachia  potentially  confers  a 
reproductive  advantage  thus  allowing  the  establishment  of  transgenics  in  the 
environment.93  Cyclopoid  copepods  are  invertebrate  predators  of  mosquito  larvae. 
Introduction of copepods into water containers, the typical breeding site of Aedes, can 
have  a  major  impact  on  mosquito  populations.94  The  roll  out  of  larvicidal 
interventions  requires  active  community  involvement  and  the  success  of  such 
measures would depend on imaginative public health engagement.94 
 
Conclusions 
Successfully tackling the threat of dengue represents a major public health challenge 
for the 21st century. A coordinated multidisciplinary approach is necessary. Major 
advances are possible provided dengue research receives the attention and funding its 
prevalence deserves. References 
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